SAN.PA · PEAD → 0

Sanofi reported Q3 2026 EPS of €3.55 on 2026-10-30, beating the €2.84 consensus by €0.71 (+25.0%).

Print-day reaction was +4.71% versus the prior close, a sharp gap-and-hold on the earnings beat. The overnight gap into T+1 gave back a modest 0.78%, suggesting some profit-taking after the strong print-day surge. Over the following two trading sessions the stock drifted an additional +4.30%, sustaining the upward momentum through 2026-11-04. Despite a robust 3-day total return of +10.44%, the benchmark 3-day return is unavailable, leaving the cumulative abnormal return uncalculated; PEAD verdict is none with conviction 0, holding window nominal through 2027-01-27.